<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136847</url>
  </required_header>
  <id_info>
    <org_study_id>Bellmed003</org_study_id>
    <nct_id>NCT04136847</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Tolerability of the SkinPen on Male and Female Subjects' Dorsal Hands as a Treatment for Signs of Hand Aging</brief_title>
  <official_title>A Single-Center Trial to Evaluate the Efficacy and Tolerability of the SkinPen on Male and Female Subjects' Dorsal Hands as a Treatment for Signs of Hand Aging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellus Medical, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellus Medical, LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Microneedling is a relatively new, minimally invasive technique originally developed for skin&#xD;
      rejuvenation. Controlled micro-injury to the dermis via the application of several small&#xD;
      needles connected to a motorized device stimulates the wound healing process, resulting in&#xD;
      the formation of new tissue and blood vessels. The SkinPen by Bellus Medical is an&#xD;
      FDA-cleared microneedling device proven to improve the appearance of acne scars This study&#xD;
      evaluates the clinical performance of the SkinPen device for the treatment of signs of aging&#xD;
      on the back of the hand.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SkinPen microneedling treatment of dorsal hand skin This is a single-site, non-randomized,&#xD;
      non-controlled study designed to follow at least twenty&#xD;
&#xD;
      three (23) qualified and consenting subjects treated with 4 Skinpen microneedling treatments.&#xD;
      The sample size determination of this study is based on the recommendations of the sponsor.&#xD;
      These patients will be treated four times over the dorsum of the hand from the wrist to the&#xD;
      knuckles each month for four months, followed by two follow-up visits at 1-month and 3-months&#xD;
      post-treatment. The acute effects of microneedling will be determined by subjective and&#xD;
      objective analysis using standard and close-up photography. Additionally, the effects of this&#xD;
      treatment will be analyzed at 1-month and 3-month post-treatment through clinician and&#xD;
      subject assessments.&#xD;
&#xD;
      Subjects will be identified from Dr. Jeffrey Kenkel's clinical practice at the University of&#xD;
      Texas Southwestern Medical Center. Subjects will be numbered sequentially in the order in&#xD;
      which they qualify for entry into the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to COVID 19 the Study did not start enrolling&#xD;
  </why_stopped>
  <start_date type="Actual">January 10, 2020</start_date>
  <completion_date type="Actual">May 26, 2020</completion_date>
  <primary_completion_date type="Actual">May 26, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>At least twenty three (23) qualified and consenting subjects treated with 4 Skinpen microneedling treatments.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aesthetic Assessment of change</measure>
    <time_frame>6 months</time_frame>
    <description>Clinician's global aesthetic improvement assessment (CGAIS) , a 5 point grading scale where 1 is ''Very Much Improved'' and 5 is ''Worse''</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aesthetic Assessment</measure>
    <time_frame>6 months</time_frame>
    <description>Subject's global aesthetic improvement assessment (CGAIS) , a 5 point grading scale where 1 is ''Very Much Improved'' and 5 is ''Worse''</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Monitoring of adverse events throughout the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin density</measure>
    <time_frame>6 months</time_frame>
    <description>Ultrasound Imaging System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Firmness</measure>
    <time_frame>6 months</time_frame>
    <description>BTC 2000</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessments of aging signs</measure>
    <time_frame>6 months</time_frame>
    <description>Measurements acquired by the VISIA Complexion Analysis System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction assessment</measure>
    <time_frame>6 months</time_frame>
    <description>Patient Satisfaction Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Hand Aging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microneedling treatment of the dorsum of the hands</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SkinPen Precision</intervention_name>
    <description>Surgical instrument motors and accessories/attachments/Hydrogel</description>
    <arm_group_label>Hand Aging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women 50 to 75 years of age having general good health.&#xD;
&#xD;
          2. Individuals deemed by the Investigator, visually, to have signs of hand aging&#xD;
             (presence of skin laxity, age spots, trophic changes) on the dorsum of the hand..&#xD;
             Also, Subjects would have to be willing to undergo correction of these signs of aging.&#xD;
&#xD;
          3. Individuals willing to withhold aesthetic therapies to the areas of the hand being&#xD;
             treated or judged to potentially impact results by the Investigator (e.g. soft tissue&#xD;
             fillers and/or any resurfacing procedures, botulinum toxin, injectable fillers,&#xD;
             microdermabrasion, IPL (intense pulsed light), peels, laser treatments, and tightening&#xD;
             treatments, etc.) for the duration of the study. Waxing and threading is allowed but&#xD;
             not laser hair removal.&#xD;
&#xD;
          4. Individuals that are willing to provide written informed consent&#xD;
&#xD;
          5. Individuals willing to sign a photography release.&#xD;
&#xD;
          6. Willingness to cooperate and participate by following study requirements for the&#xD;
             duration of the study and to report any changes in health status or medications,&#xD;
             adverse event symptoms, or reactions immediately.&#xD;
&#xD;
          7. Women of child bearing potential agree to take a urine pregnancy test at the Baseline&#xD;
             visit and 3-months post-treatment or when deemed by Investigator and/or Sponsor. This&#xD;
             may be changed to a monthly pregnancy test at the Sponsor's discretion. Women who are&#xD;
             of childbearing potential must have a negative urine pregnancy test result and must&#xD;
             not be lactating at the baseline visit. Women must be willing and able to use an&#xD;
             acceptable method of birth control (e.g. barrier methods used with a spermicidal&#xD;
             agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study.&#xD;
             Women will not be considered of childbearing potential if one of the following&#xD;
             conditions is documented on the medical history:&#xD;
&#xD;
               -  Postmenopausal for at least 12 months prior to study;&#xD;
&#xD;
               -  Without a uterus and/or both ovaries;&#xD;
&#xD;
               -  Bilateral tubal ligation at least 6 months prior to study enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Individuals diagnosed with known allergies to general skin care products.&#xD;
&#xD;
          2. Individuals who have presence of an active systemic or local skin disease that may&#xD;
             affect wound healing.&#xD;
&#xD;
          3. Individuals who have severe solar elastosis.&#xD;
&#xD;
          4. Individuals with sensitivity to topical lidocaine.&#xD;
&#xD;
          5. Individuals who have physical or psychological conditions unacceptable to the&#xD;
             Investigator.&#xD;
&#xD;
          6. Individuals who have a recent history of significant trauma to the areas to be treated&#xD;
             (&lt; 6 months).&#xD;
&#xD;
          7. Individuals who have significant scarring in the area(s) to be treated.&#xD;
&#xD;
          8. Individuals who have a recent or current history of inflammatory skin disease,&#xD;
             infection or unhealed wound.&#xD;
&#xD;
          9. Individuals who have a history of systemic granulomatous diseases, active or inactive,&#xD;
             (e.g. Sarcoid, Wegeners, TB, etc.) or connective tissue diseases (e.g. lupus,&#xD;
             dermatomyositis, etc.).&#xD;
&#xD;
         10. Individuals who currently have or have a history of hypertrophic scars, or keloid&#xD;
             scars.&#xD;
&#xD;
         11. Individuals who currently have cancerous or pre-cancerous lesions in the areas to be&#xD;
             treated and/or with a history of skin cancer.&#xD;
&#xD;
         12. Individuals who have the inability to understand instructions or to give informed&#xD;
             consent.&#xD;
&#xD;
         13. Individuals who have had microdermabrasion or glycolic acid treatment to the treatment&#xD;
             area(s) within one month prior to study participation or who will have this treatment&#xD;
             during the study.&#xD;
&#xD;
         14. Individuals who have a history of chronic drug or alcohol abuse.&#xD;
&#xD;
         15. Individuals undergoing concurrent therapy that, in the Investigator's opinion, would&#xD;
             interfere with the evaluation of the safety or efficacy of the study device.&#xD;
&#xD;
         16. Individuals who, in the Investigator's opinion, have a history of poor cooperation,&#xD;
             noncompliance with medical treatment, or unreliability.&#xD;
&#xD;
         17. Individuals who are current smokers or have smoked in the last five years.&#xD;
&#xD;
         18. Individuals who have a history of the following cosmetic treatments in the area(s) to&#xD;
             be treated:&#xD;
&#xD;
               -  Skin tightening procedure within the past year;&#xD;
&#xD;
               -  Injectable filler of any type within the past:&#xD;
&#xD;
                    -  12 months for Hyaluronic acid fillers (e.g. Restylane)&#xD;
&#xD;
                    -  12 months for Ca Hydroxyapatite fillers (e.g. Radiesse)&#xD;
&#xD;
                    -  24 months for Poly-L-Lactic acid fillers (e.g. Sculptra)&#xD;
&#xD;
                    -  Ever for permanent fillers (e.g. Silicone, ArteFill)&#xD;
&#xD;
               -  Neurotoxins within the past three months;&#xD;
&#xD;
               -  Ablative resurfacing laser treatment;&#xD;
&#xD;
               -  Non-ablative, rejuvenative laser or light treatment within the past six months;&#xD;
&#xD;
               -  Surgical dermabrasion;&#xD;
&#xD;
               -  Had a chemical peel or dermabrasion, of the dorsum of the hand within four weeks&#xD;
&#xD;
         19. Individuals with a history of using the following prescription medications:&#xD;
&#xD;
               -  Accutane or other systemic retinoids within the past six months;&#xD;
&#xD;
               -  Topical Retinoids within the past two weeks;&#xD;
&#xD;
               -  Prescription strength skin lightening devices (e.g. hydroquinone, tretinoin, AHA,&#xD;
                  BHA and polyhydroxy acids, 4-hydroxyanisole alone or in combination with&#xD;
                  tretinoin, etc.) within four months;&#xD;
&#xD;
               -  Any anti-wrinkle, skin lightening devices, or any other device or topical or&#xD;
                  systemic medication known to affect skin aging or dyshcromia (devices containing&#xD;
                  alpha/beta/poly-hydroxy acids, vitamin C, soy, Q-10, hydroquinone; systemic or&#xD;
                  licorice extract (topically), TegoÂ® Cosmo C250, gigawhite, lemon juice extract&#xD;
                  (topically), emblica extract, etc.) within two weeks;&#xD;
&#xD;
               -  Antiplatelet agents/Anticoagulants (Coumadin, Heparin, Plavix, chronic NSAID&#xD;
                  use); and/or&#xD;
&#xD;
               -  Psychiatric drugs that in the Investigator's opinion would impair the subject&#xD;
                  from understanding the protocol requirements or understanding and signing the&#xD;
                  informed consent.&#xD;
&#xD;
         20. Individuals who are nursing, pregnant, or planning to become pregnant during the study&#xD;
             according to subject self-report.&#xD;
&#xD;
         21. Individuals having a health condition and/or pre-existing or dormant dermatologic&#xD;
             disease on the body (e.g., psoriasis, rosacea, eczema, seborrheic dermatitis,&#xD;
             vitiligo, hyper or hypo-skin pigmentation conditions such as post inflammatory&#xD;
             hyperpigmentation) that the Investigator or designee deems inappropriate for&#xD;
             participation or could interfere with the outcome of the study.&#xD;
&#xD;
         22. Individuals with a history of immunosuppression/immune deficiency disorders (including&#xD;
             HIV infection or AIDS) or currently using immunosuppressive medications (e.g.,&#xD;
             azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate&#xD;
             mofetil, methotrexate, prednisone, Remicade, Stelara.) and/or radiation as determined&#xD;
             by study documentation.&#xD;
&#xD;
         23. Individuals with an uncontrolled disease such as asthma, diabetes, hyperthyroidism,&#xD;
             medically significant hypertension or hypothyroidism. Individuals having multiple&#xD;
             health conditions may be excluded from participation even if the conditions are&#xD;
             controlled by diet, medication, etc.&#xD;
&#xD;
         24. Individuals with any planned surgeries, overnight hospitalization, and/or invasive&#xD;
             medical procedures during the course of the study.&#xD;
&#xD;
         25. Individuals who have observable suntan, nevi, excessive hair, etc. or other dermal&#xD;
             conditions on the back of the hand that might influence the test results in the&#xD;
             opinion of the Investigator or designee.&#xD;
&#xD;
         26. Individuals who have any condition, which in the opinion of the Investigator makes the&#xD;
             patient unable to complete the study per protocol (e.g. patients not likely to avoid&#xD;
             other cosmetic treatments to the treatment area; patients not likely to stay in the&#xD;
             study for its duration because of other commitments, concomitant conditions, or past&#xD;
             history; patients anticipated to be unreliable, or patients who have a concomitant&#xD;
             condition that may develop symptoms that might confuse or confound study treatments or&#xD;
             assessments).&#xD;
&#xD;
         27. Individuals who started hormone replacement therapies (HRT) or hormones for birth&#xD;
             control less than three months prior to study entry or who plan on starting, stopping,&#xD;
             or changing doses of HRT or hormones for birth control during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Kenkel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTSW</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 17, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Signs of Hand Aging</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

